A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Lebrikizumab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms treble
  • Sponsors Roche
  • Most Recent Events

    • 04 May 2016 Status changed from recruiting to completed.
    • 02 Nov 2015 Planned End Date changed from 1 Dec 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
    • 02 Nov 2015 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top